Pulse Biosciences Q1 FY26 net loss widens to $18.58 million

Pulse Biosciences, Inc.

Pulse Biosciences, Inc.

PLSE

0.00
  • Pulse Biosciences posted a wider net loss of USD 18.58 million for the quarter ended March 31, 2026, compared with USD 16.8 million a year earlier.
  • Revenue turned positive to USD 401,000, driven by limited market release commercial sales of the Vybrance Percutaneous Electrode System.
  • Operating loss widened to USD 19.15 million as research and development expense rose to USD 12.59 million.
  • Selling, general and administrative expense fell to USD 6.59 million, while interest income slid to USD 593,000.
  • Cash and cash equivalents totaled USD 68.3 million at March 31, 2026; Pulse expects existing resources plus net proceeds from a May 2026 at-the-market sale of USD 12.9 million to fund operations for at least 12 months from the filing date.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-016897), on May 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.